HK2 and glioblastoma: Using The Cancer Genome Atlas (TCGA) data set of 529 samples, we selected the top and bottom 10% of HK2 expressing patient samples (n = 50 per group) at the RNA level to identify molecular or clinically aggressive features of GBM associated with HK2 (Figure 1A).